Treatment Options in Patients With Chronic GVHD

Mechanism of Action Influences Sequencing of Systemic GVHD Therapies

Noah M. Merin, MD, PhD, discusses the mechanisms of action and sequencing of oral therapies for chronic graft-vs-host disease (GVHD) in a live virtual event.

Approved Therapies Considered for Patients With Graft-Vs-Host Disease

Noah M. Merin, MD, PhD, discusses approved therapies in acute and chronic graft-vs-host disease.

Acknowledging Different Considerations for Ruxolitinib in Severe GVHD

In the second article of a 2-part series, Lori Muffly, MD, MS, leads a discussion on how treatment considerations change when a patient has severe graft-vs-host disease or if the involvement is in the lung and where ruxolitinib fits into treatment.

Different Approaches Available for Identifying and Managing Chronic GVHD

In the first article of a 2-part series, Lori Muffly, MD, MS, discusses with a panel of physicians what their approach is to identifying patients with severe chronic graft-versus-host-disease and how they treat them in conjunction with the transplant team.

Identifying When Additional Treatment Is Needed for cGVHD

During a Targeted Oncology™ Case-Based Roundtable™ event, Carrie L. Kitko, MD, discussed whether to biopsy a patient with chronic GVHD and what treatment to use following steroids.

Using NCCN Guidelines for Chronic GVHD Therapy in Clinical Practice

During a Targeted Oncology™ Case-Based Roundtable™ event, Noah M. Merin, MD, PhD, discussed 3 recommended agents for treatment of chronic graft-vs-host disease. This is the second of 2 articles based on this event.

Biology Informs Treatment Options for Steroid-Refractory Chronic GVHD

During a Targeted Oncology™ Case-Based Roundtable™ event, Noah M. Merin, MD, PhD, discussed biologic phases of chronic graft-vs-host disease and which therapies are available for patients who do not respond to steroids.